Defining Best Practice in Early and Managed Access Programmes for the Global Pharmaceutical Industry
Pharma, biotech and life sciences companies are under increasing pressure from patients and physicians alike to provide early access programmes (EAPs) to orphan and investigational drugs. As a result the need to understand the challenges associated with these complex programmes and develop a roadmap for succesful planning and execution of EAPs increases with it.
The Early Access Programmes Summit - the world's first and most prestigious EAP event - returns in November 2016, where the leading figures in early and managed access programmes will be tackling the challenges at the very heart of the issues within this complex field.
Key Challenges and Topics of Debate Include:
Anticipating demand and make the decision on whether to run an EAP: risk vs benefit, safety data, resources and stakeholder engagement
Navigating the minefield of country-specific regulatory requirements on a global scale
Developing an effective planning strategy to forecast and establish accurate drug supply
Ensuring equitable drug supply allocation
Successfully implementing, monitoring and closing out an EAP
Understanding the patient perspective and utilising independent bodies to facilitate and support EAPs
Register your place at the world's foremost managed access event, taking place in London this November! The two days of industry leading insight will include case studies from leading pharmaceutical companies including Pfizer, Shire, Johnson and Johnson, Sanofi and many more, who are making significant steps on the road to overcome these challenges, implementing and executing successful EAPs and MAPs around the world.
2016 Speakers Include:
Strategy&, part of the PwC network
Associate Consumer Lead
National Cancer Research Institute (NCRI)
Head of EU Advocacy
Group Chief Medical Officer
President & CEO
Cognition Therapeutics, Inc.
Head of Bioethics
New York University Langone Medical Center
Sr. Global Brand Medical Director
Novartis Pharma AG
Chief Medical Officer
Johnson & Johnson
What is the industry saying about Pharma IQ's events?
"Extremely valuable"Policy Director, AstraZeneca, Delegate 2015
"My knowledge has increased, which I can take back to my organisation"Business Development, MultiPharma, Delegate 2015
"A valuable event providing lots of very useful information and relevant contacts" GMP/GDP Systems Manager, Intercept Pharmaceuticals, Delegate 2015
"Good event, good networking opportunities and relationship building." Regulatory Affairs Manager, Idis, Delegate 2015